Fosun Pharma YP01001 capsule clinical trial application accepted

On January 12, Fosun Pharma announced that its controlling subsidiary, Chongqing Pharmaceutical Friends Pharmaceuticals, had received a "notice of acceptance" and that the YP01001 capsules it had participated in the development of for the treatment of advanced solid tumors (liver cancer, stomach cancer, etc.) had been approved by the State Drug Administration for clinical trial registration and review.
The new drug is an innovative small molecule chemical drug intended to be used to treat advanced solid tumors (liver cancer, stomach cancer, etc.);
as of the date of this announcement, the new drug listed in China (excluding Hong Kong, Macao and Taiwan, the same as between 2007) has methyl sulfonate lenphatini capsules and so on.
based on IQVIA CHPA data (provided by IQVIA, IQVIA is the world's leading provider of professional information and strategic consulting services for the pharmaceutical and health industry; Due to the different distribution of their respective sales channels, actual sales may differ to varying degrees from IQVIA CHPA data), and sales of methyl sulfate lenphatini capsules in China in 2019 were approximately RMB22 million.
as of November 2020, the Group's cumulative research and development investment in the new drug at this stage is approximately RMB30.59 million (unaudited).